15 minutes to Read

Despite limited indications, amoxicillin + clavulanic acid remains the second most used antibiotic in Aotearoa after amoxicillin. Inappropriate use of antibiotics may stem partly from meeting patient expectations for treatment. Read our case study to find out more.

Lauren Smith
14 March 2023
11 minutes to Read

Antimicrobial resistance presents an imminent threat to the future of New Zealanders’ wellbeing and access to effective, safe healthcare. This article describes initiatives for improving antimicrobial stewardship, the New Zealand antimicrobial prescribing landscape as it stands, and actions that can be taken immediately in primary care.

He Ako Hiringa, reviewed by Dr Sharon Gardiner
15 November 2022
2 minutes to Read

The ACE inhibitor cilazapril will soon be delisted – new alternatives include ramipril capsules and an 8mg perindopril tablet.

This article summarises recent and upcoming changes to ACE inhibitor availability, and provides a dose equivalence table and advice for switching between medicines.

He Ako Hiringa, reviewed by Dr Noni Richards
14 November 2022
5 minutes to Read

The antihypertensive medicine Accuretic (quinapril with hydrochlorothiazide) is being withdrawn (Pfizer pulled stock from distribution on 31 October 2022).

Prescribers are advised to change patients from Accuretic to alternative medicine(s) with some urgency. Read our article for dose equivalence tables and information on switching, monitoring, co-payments and consultation fees.

Dr Noni Richards
4 July 2022
4 minutes to Read + 56 minutes to Delve

This workbook consists of introductory reading and five distinct modules that encourage you to reflect on your CVD risk assessment and management practices, risk communication, cultural safety, and your engagement with young adult Māori and Pacific patients.

Richard French, Dr Noni Richards
21 April 2022
13 minutes to Read + 47 minutes to Delve

This article summarises the 2022 changes regarding adalimumab funding and access in New Zealand. It also provides some background and resources to foster confidence in biosimilars, and references real-world data from studies of patients changing from Humira to Amgevita.

He Ako Hiringa
14 February 2022
10 minutes to Read + 2 minutes to Watch

Rosuvastatin is now fully funded on Special Authority for people at increased risk of cardiovascular complications due to high cholesterol, and may be considered first-line for Māori and Pacific peoples.

An abridged version of this article, containing the eligibility flowchart, is available for printing - see the link in the contents box. 

He Ako Hiringa
15 November 2021